To the Editor: Regarding the position statement about COX-2 inhibitors, we agree that openness about all potential conflicts of interest is the least we should expect from guideline developers, but this is not enough.1 Fifteen (65%) of the 23 members of the Australian COX-2 Specific Inhibitor Prescribing Group (including all eight of the rheumatologists involved) declared current financial links with Pfizer and Merck, Sharp and Dohme, the two drug companies marketing COX-2 inhibitors in Australia.2 The Prescribing Group can be viewed at best as a tight collaboration between some healthcare professionals and drug companies. At worst the statement published in the Journal can be seen as the "happy end" of a successful marketing campaign, which began some years ago with the enrolment of the most influential Australian rheumatologists to the advisory boards of the drug companies.3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Edmonds JP, Day RO, Bertouch JW. The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors. Med J Aust 2002; 176: 332-334. <MJA full text>
- 2. The Australian COX-2 specific Inhibitor (CSI) Prescribing Group. Considerations for the safe prescribing and use of COX-2-specific inhibitors. Med J Aust 2002; 176: 328-331. <eMJA full text>
- 3. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002; 324: 886-891.
- 4. Healthy Skepticism <http://www.healthyskepticism.org>. Accessed 10 September 2002.
- 5. US Food and Drug Administration. Celebrex capsules (celecoxib). NDA 20-998/S-009. Medical officer review. 20 September 2000. <http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf>. Accessed 10 September 2002.
- 6. Jüni P, Rutjes A, Dieppe P. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-1288.
- 7. Silverstein FE, Faich G, Reicin A, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis — the CLASS study: a randomized controlled trial. JAMA 2000; 281: 1247-1255.
- 8. Health Insurance Commission. Health Statistics. Pharmaceutical Benefits Scheme. <http://www.medicareaustralia.gov.au/providers/health_statistics/statistical_reporting/pbs.htm>. Accessed 10 September 2002, link updated Nov 2005.
- 9. Graudins L. Celecoxib prescribing — drug use review in a Sydney teaching hospital. Quality Use of Medicines Mapping Project. <http://www.qummap.health.gov.au/plist.asp?project=988>. Accessed 10 September 2002.